🔗 Permalink

Inventor profile of:

Frédéric Triebel

City:

Versailles

Country:

France

Published Applications:

Last publication date:

2025-12-18

Top Assignees for applications by Frédéric Triebel

The entities that hold a legal rights for patent applications filed by inventor Triebel Frédéric:

Immutep S.A.S. 13 Orsay, France
NOVARTIS AG 4 Basel, Switzerland
IMMUTEP 3 ORSAY, France
Immutep S.A.S. 2 SAINT-AUBIN, France
IMMUTEP 2 SAINT-AUBIN, France
INSTITUT GUSTAVE ROUSSY 2 Villejuif, France
Immutep S.A.S. 1 , France
Immutep Parc Club Orsay 1 Orsay, France
INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) 1 Paris, France
Novartis, AG 1 , Switzerland
IMMUTEP PARC CLUB ORSAY 1 ORSAY CEDEX, France
Institut Gustave Roussy 1 Villejif, France
Applied Research Systems ARS Holding N.V. 1 , Netherland Antilles
INSERM (Institut National de la Sante et de la Recherche Medicale) 1 Paris Cedex, France
Cell Genesys, Inc. 1 South San Francisco, CA United States
Immutep S.A. 1 Orsay cedex, France

Recent patent applications by Triebel Frédéric

Frédéric Triebel from Versailles, FR has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-12-18

US20250382365A1

Chemistry; metallurgy

ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF

#2 | 2025-04-24

US20250127856A1

Human necessities

COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER

#3 | 2023-10-19

US20230330182A1

Human necessities

COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER OR INFECTION

#4 | 2023-08-31

US20230272107A1

Chemistry; metallurgy

ANTI-LAG-3 ANTIBODIES

#5 | 2023-05-18

US20230149541A1

Human necessities

USE OF RECOMBINANT LAG-3 OR THE DERIVATIVES THEREOF FOR ELICITING MONOCYTE IMMUNE RESPONSE

#6 | 2023-03-09

US20230074746A1

Human necessities

COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER OR INFECTION

#7 | 2022-05-19

US20220153835A1

Chemistry; metallurgy

COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO LAG-3

#8 | 2021-06-17

US20210177937A1

Human necessities

Combined preparations for the treatment of cancer or infection

#9 | 2021-01-14

US20210009687A1

Chemistry; metallurgy

Antibody molecules to LAG-3 and uses thereof

#10 | 2020-10-15

US20200323957A1

Human necessities

Combined preparations for the treatment of cancer

#11 | 2020-04-23

US20200121757A1

Human necessities

Combined preparations for the treatment of cancer or infection

#12 | 2019-06-13

US20190175726A1

Human necessities

Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response

#13 | 2019-05-23

US20190153112A1

Chemistry; metallurgy

Anti-LAG-3 antibodies

#14 | 2018-11-29

US20180340025A1

Chemistry; metallurgy

COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO LAG-3

#15 | 2018-09-27

US20180271940A1

Human necessities

Combined preparations for the treatment of cancer or infection

#16 | 2018-03-29

US20180086830A1

Chemistry; metallurgy

Antibody molecules to LAG-3 and uses thereof

#17 | 2017-07-27

US20170210804A1

Chemistry; metallurgy

Antibody molecules to LAG-3 and uses thereof

#18 | 2017-05-04

US20170119876A1

Human necessities

Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response

#19 | 2016-10-27

US20160310570A1

Human necessities

Combined preparations for the treatment of cancer

#20 | 2016-06-23

US20160176965A1

Chemistry; metallurgy

CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE

#21 | 2015-09-17

US20150259420A1

Chemistry; metallurgy

ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF

#22 | 2011-03-24

US20110070238A1

Chemistry; metallurgy

Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease

#23 | 2011-01-13

US20110008331A1

Human necessities

Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response

#24 | 2010-09-16

US20100233183A1

Chemistry; metallurgy

CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE

#25 | 2009-05-21

US20090130054A1

Human necessities

Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use

#26 | 2006-09-19

US10041600

Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment

#27 | 2005-04-05

US10019219

Peptide compounds derived from a shifted ORF of the iCE gene

#28 | 2005-02-15

US9673795

Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapy

InventorID:

1288831 ⎘